TetraGraph Poster and Abstract presentation at The Society for Technology in Anesthesia (STA) 2018
News; Uppsala, January 19, 2018. The STA 2018 Annual Meeting in Turnberry Isle Miami Aventura, Florida, January 10-13, is designated for a national and international audience of physicians, engineers and industry members, as well as other practitioners in the field of anesthesia seeking an update on the current and future state of anesthesia technology. https://www.stahq.org/events/annual-meeting
During the meeting, Reka Nemes, MD, Mayo Clinic, Jacksonville, Florida presented an abstract and poster entitled, “Comparison of electromyography derived train-of-four ratios of the adductor pollicis and abductor digiti minimi muscles and their comparison to acceleromyography derived train-of-four ratios.”
The pilot study investigated the TetraGraph, an electromyography (EMG)-based monitor that uses proprietary surface strip electrodes (TetraSens) for ulnar nerve stimulation, while recording compound muscle action potentials from the adductor pollicis (mAP) or the abductor digiti minimi (mADM) muscles. The study aim was to compare the correspondence of the two hand muscles’ EMG-derived TOF ratios (%), and to examine the agreement between EMG and acceleromyographic (AMG) measurements.
Unlike AMG-based monitors, the TetraGraph is able to record multiple different hand muscles such as the mAP and mADM. These recordings were easy to perform with the TetraGraph, and confirmed that these muscles have different onset and recovery times. Knowing which muscle is being monitored has important clinical implications on the appropriate timing of reversal of neuromuscular block.
For further information, please contact:
Catrin Molund, Business Development Director
Tel: +46-708-11 69 11,
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
Tags:
